Vaccitech Appoints CEO

Vaccitech has appointed Bill Enright as its new Chief Executive Officer. Mr. Enright succeeds Tom Evans, MD who will make a planned transition to the role of Vaccitech’s Chief Scientific Officer.
 
Bill joins Vaccitech after an accomplished 11 years as CEO at Gaithersburg-based Altimmune Inc., where he led Altimmune through a significant period of growth including a Series B financing, the acquisition of Immune Targeting Systems - a UK T-cell vaccine company - and taking the company public on NASDAQ through the acquisition of PharmAthene. Bill’s prior experience includes executive and management roles at GenVec (now Intrexon), Biotech Venture Management and Life Technologies Corporation (now ThermoFisher).
 
Dr. Andrew McLean, Vaccitech Board Member, Oxford Science Innovation, said, "We’re incredibly excited to welcome Bill Enright to lead Vaccitech to build a world-leading T-cell induction immunotherapy company."
 
"We believe that Bill’s background and leadership skills are well suited to the Company’s next phase of development and are looking forward to welcoming him to the role. We are extremely grateful to Tom Evans under whose leadership the company has grown rapidly, with over 2000 participants currently in clinical trials. We look forward to Tom’s continuing involvement and excellent scientific leadership as Vaccitech’s CSO," added Robin Wright, Vaccitech Chairman.

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.